Altered SRD5A2 Gene Methylation in PFS Patients
Pilot study links altered SRD5A2 gene methylation in CSF with behavioral symptoms in Post-Finasteride Syndrome.
Altered Methylation Patterns of the SRD5A2 Gene in Post-Finasteride Syndrome Patients: A Pilot Study
This pilot study investigates the epigenetic modifications in patients suffering from Post-Finasteride Syndrome (PFS). The researchers focused on the methylation patterns of the SRD5A1 and SRD5A2 gene promoters in cerebrospinal fluid (CSF) and blood samples. The study included 16 PFS patients and 20 age-matched healthy controls.
The results revealed that the SRD5A2 promoter was significantly more methylated in the CSF of PFS patients compared to the controls, while no methylation was detected in blood samples. This methylation may play a crucial role in the altered neuroactive steroid levels observed in PFS patients, potentially leading to the behavioral disturbances associated with the syndrome.
These findings suggest that finasteride treatment may lead to tissue-specific epigenetic changes, which could underlie the persistent symptoms seen in PFS. However, it remains unclear whether these methylation patterns are established prenatally or induced by finasteride treatment itself.
For more detailed information, you can access the original article, Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study.
This information does not replace medical advice. Talk to your doctor before you make any decision about your treatment.
580+ people have joined the community.
Join them, then report your side effects.
- Put your condition on the record
- Be first to hear about studies you can join
- Then report your side effects to your regulator